UC Irvine Health

Malignant Hematology Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center



Epidemiologic

UCI-13-02 Assessing Fitness and Physical Activity in Acute Lymphoblastic Leukemia (ALL) Patients in Remission (Aizik)

Correlative

UCI-14-03 Role of inflammation in the pathogenesis of myeloproliferative neoplasm (Fleischman)

UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)

UCI-16-70 Evaluation of Mitochondrial Priming in T Cell Lymphomas (Brem)

UCI 15-65** Effect of candidate blood cancer therapies on normal human lymphocytes (Fruman)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

V.0818

**Opening soon

CLL

UCI 16-95

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies (O'Brien)

UCI 15-18

An Open-Label, Multicenter Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy (O'Brien)

UCI 17-19 (CLL/SLL/Richters)

A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (O'Brien)

UC Irvine Health

Malignant Hematology Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center

ALL

ECOG E1910
A phase II Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia (ALL) (Jeyakumar)

UCI 16-13**
A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)

SWOG S1318 (Ph- Only) *SUSPENDED*
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 18 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia- Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (Jeyakumar)

UCI 14-95
A Phase 1/2 Study of the Blinatumomab in Combination with the PD-1 Inhibitor Pembrolizumab (MK-3475) for the Treatment of Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia (Jeyakumar)

UCI 15-58
SUSPENDED
A Phase I/II Study Evaluating KTE-C19 in Subjects with Relapsed/Refractory ALL (O'Brien)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

V.0818

**Opening soon

UC Irvine Health

Malignant Hematology Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center

Lymphoma

UCI 17-47
A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with EBV-Associated Lymphoid Malignancies. (Brem)

UCI 16-13**
A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)

UCI 16-95
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients with B-Lymphoid Malignancies (O'Brien)

UCI 17-19 (T-Cell/NHL)
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies

UCI 15-18
An Open-Label, Multicenter Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy (O'Brien)

UCI 16-46
A Phase 1 dose-ranging study to investigate the safety, tolerability and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous, and intravenous administration in subjects with various lymphomas and leukemias (Pinter-Brown)

UCI 17-70
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma (Pinter-Brown)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

V.0818

**Opening soon

T-Cell Lymphoma

UCI 17-19 (T-Cell/NHL)
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (O'Brien)

UCI 17-36
A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma. (Pinter-Brown)

UCI 17-82
A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA. (Pinter-Brown)

UC Irvine Health

Malignant Hematology Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center

AML

UCI 16-100

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy (Jeyakumar)

UCI 17-02 *Suspended*

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects with Metastatic Castrate Resistant Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) (Jeyakumar)

UCI 16-13**

A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)

UCI 17-114

A Randomized (1:1), Double-Blind, Multi-Center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF-04449913) or Azacitidine (AZA) With or Without Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia (O'Brien)

UCI 18-09

A Phase 1b Study of Venetoclax and Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (Jeyakumar)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

V.0818

**Opening soon

UC Irvine Health

Malignant Hematology Clinical Trials

Chao Family Comprehensive Cancer Center
A National Cancer Institute-Designated Comprehensive Cancer Center

MPN

UCI 17-31
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis (Fleischman)

UCI 18-30**
Nutritional Intervention Among Myeloproliferative Neoplasm: Feasibility Phase (The NUTRIENT Trial) (Fleischman)

MDS

UCI 14-93
Phase 1b Study of Ibrutinib and Azacitidine for the treatment of patients with higher risk MDS (Jeyakumar)

UCI 16-13**
A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies (Jeyakumar)

MALIGNANT HEMATOLOGY

ECOG-EAY131
Molecular Analysis for Therapy Choice (MATCH) (Bota)

Multiple Myeloma

ECOG E1A11
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) (Brem)

UCI 17-19 (Myeloma)
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies (O'Brien)

UCI 14-96
A Phase I/II Study of PiC-D (Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone) in Patients with Double Refractory Multiple Myeloma (Brem)

For more details contact 1-877-UC-Study OR ucstudy.uci.edu

V.0818

**Opening soon